Eisai has won full FDA approval for its Alzheimer’s disease drug, a regulatory decision that sets precedent for the review and potential approval of other therapies for the neurodegenerative disorder. However, while conversion of Leqembi’s accelerated approval to traditional approval was…
Source: medcitynews.com – Read more
China-Linked TA416 Targets European Governments with PlugX and OAuth-Based Phishing – thehackernews.com
China-Linked TA416 Targets European Governments with PlugX and OAuth-Based Phishing thehackernews.com
